These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26578705)

  • 1. New hopes in the fight against cancer: a special issue on targeted anti-cancer drug discovery and cell signaling.
    Cheng X
    Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):1-2. PubMed ID: 26578705
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial overview: cancer: from target discovery to targeted therapy: the risky business of target validation.
    Cruzalegui F
    Curr Opin Pharmacol; 2014 Aug; 17():iv-vi. PubMed ID: 25220882
    [No Abstract]   [Full Text] [Related]  

  • 3. Meeting Report: The 8th Barossa Meeting-Cell Signaling in Cancer Medicine in the Barossa Valley, Australia.
    Gomez GA; Woodcock JM; Tergaonkar V; Gregory PA
    Cell Death Dis; 2018 Feb; 9(3):284. PubMed ID: 29449550
    [No Abstract]   [Full Text] [Related]  

  • 4. Epistatic interactions and drug response.
    Weigelt B; Reis-Filho JS
    J Pathol; 2014 Jan; 232(2):255-63. PubMed ID: 24105606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of acquired resistance to targeted cancer therapies.
    Lackner MR; Wilson TR; Settleman J
    Future Oncol; 2012 Aug; 8(8):999-1014. PubMed ID: 22894672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic Regulation and Drug Discovery for Cancer Therapy.
    Yu B; Ouyang L
    Curr Top Med Chem; 2019; 19(12):971. PubMed ID: 31486748
    [No Abstract]   [Full Text] [Related]  

  • 7. Epigenetic opportunities and challenges in cancer.
    Best JD; Carey N
    Drug Discov Today; 2010 Jan; 15(1-2):65-70. PubMed ID: 19897050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of targeted therapies in cancer: opportunities and challenges in the clinic.
    Santhosh S; Kumar P; Ramprasad V; Chaudhuri A
    Future Oncol; 2015; 11(2):279-93. PubMed ID: 25591839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic alterations as the basis for resistance to targeted therapies.
    Blair BG; Bardelli A; Park BH
    J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Signal transduction and its targeting from the cancer molecular genetic platform: applications and perspectives in pulmonary pathology].
    Merlio JP
    Ann Pathol; 2011 Nov; 31(5 Suppl):S40-2. PubMed ID: 22054456
    [No Abstract]   [Full Text] [Related]  

  • 11. New developments on targeted cancer therapy: Multi-faceted issues in targeted cancer therapy.
    Bao J; Qiao L
    Cancer Lett; 2017 Feb; 387():1-2. PubMed ID: 28038727
    [No Abstract]   [Full Text] [Related]  

  • 12. The development and potential clinical utility of biomarkers for HDAC inhibitors.
    Shi B; Xu W
    Drug Discov Ther; 2013 Aug; 7(4):129-36. PubMed ID: 24071574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical biology approaches to target validation in cancer.
    Blagg J; Workman P
    Curr Opin Pharmacol; 2014 Aug; 17():87-100. PubMed ID: 25175311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The MYC-WDR5 Nexus and Cancer.
    Thomas LR; Foshage AM; Weissmiller AM; Tansey WP
    Cancer Res; 2015 Oct; 75(19):4012-5. PubMed ID: 26383167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting chromatin.
    Nat Struct Mol Biol; 2019 Oct; 26(10):841. PubMed ID: 31582845
    [No Abstract]   [Full Text] [Related]  

  • 16. Epigenetic drugs against cancer: an evolving landscape.
    Di Costanzo A; Del Gaudio N; Migliaccio A; Altucci L
    Arch Toxicol; 2014 Sep; 88(9):1651-68. PubMed ID: 25085708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging role of CXC chemokines and their receptors in cancer.
    Vinader V; Afarinkia K
    Future Med Chem; 2012 May; 4(7):853-67. PubMed ID: 22571611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-bound enzymes as epigenetic drug targets in cancer.
    Bomsztyk K; Wang Y
    Epigenomics; 2019 Oct; 11(13):1463-1467. PubMed ID: 31536377
    [No Abstract]   [Full Text] [Related]  

  • 19. Science and mechanism of action of targeted therapies in cancer treatment.
    Wujcik D
    Semin Oncol Nurs; 2014 Aug; 30(3):139-46. PubMed ID: 25085025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic lethal vulnerabilities of cancer.
    Fece de la Cruz F; Gapp BV; Nijman SM
    Annu Rev Pharmacol Toxicol; 2015; 55():513-31. PubMed ID: 25340932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.